Dry Eye

Physicians Find Currently Available Treatments for Dry Eye Disease Lacking

Posted on

A new study published in Clinical Ophthalmology sought to assess physician satisfaction with the 2 currently available anti-inflammatory prescription treatments for dry eye disease (DED): cyclosporine ophthalmic emulsion 0.05% (CYC) and lifitegrast 5% ophthalmic solution (LIF).

In this survey-based study, 21 doctors gave responses on behalf of 210 patients and reported low satisfaction with the onset of action of CYC and LIF. In addition, fewer than half of the respondents considered the drug effective at managing symptoms or improving patient quality of life.

The most frequently reported side effects were burning sensation and dysgeusia and the main switching drivers were onset of action and effectiveness after onset.

Most physicians reported satisfaction in the overall effectiveness of CYC and LIF but all agreed that more treatment options were needed for DED.


White DE, Zhao Y, Jayapalan H, et al. Physician satisfaction with anti-inflammatory topical medications for the treatment of dry eye disease. Clin Ophthalmol. 2020:14:931-938.

Related Articles
Not All DED Patients Have Chronic Symptoms
Aug 02, 2021
Dry Eye Awareness Month: Focus on these 3 Goals
Jul 27, 2021
Systane iLux non-inferior to Lipiflow in change in meibomian gland score
Jul 25, 2021